Activated protein C was cost-effective for prolonging survival in a subgroup of patients with severe sepsis

Manns, B.J.; Lee, H.; Doig, C.J.; Johnson, D.; Donaldson, C.; Wiedemann, Herbert P.
May 2003
ACP Journal Club;May/Jun2003, Vol. 138 Issue 3, p81
Academic Journal
Summarizes a study that investigated whether treatment with recombinant human-activated protein C is more cost-effective than conventional care for prolonging survival in patients with severe sepsis. Characterization of the patients; Main cost and outcome measures; Results of the study.


Related Articles

  • Recombinant human activated protein C in severe sepsis. Mann, Henry J. // American Journal of Health-System Pharmacy;2/15/2002, Vol. 59 Issue 4, pS19 

    Protein C, a naturally occurring vitamin K-dependent serine protease in the blood, remains inactive until exposed to the thrombin-thrombomodulin complex. This change between the inactive and active forms occurs constantly in humans and serves to balance the coagulation cascade. APC functions in...

  • Fresh from the pipeline: Drotrecogin alpha (activated). Lebbos, John; Bradsher, Julia; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jan2003, Vol. 2 Issue 1, p13 

    In November 2001, drotrecogin alpha (activated) (Xigris) became the first drug to be approved by the FDA for the treatment of severe sepsis, a systemic response to infection that kills an estimated 500,000 people each year. Xigris was widely anticipated to be a blockbuster, but it has not yet...

  • Activated Protein C for Sepsis. Mackenzie, Alasdair // New England Journal of Medicine;3/25/2010, Vol. 362 Issue 12, p1150 

    A letter to the editor is presented in response to the article "Activated Protein C for Sepsis," by S. Toussaint et al. published in the December 31, 2009 issue.

  • Activated Protein C for Sepsis. Toussaint, Susanne; Gerlach, Herwig // New England Journal of Medicine;3/25/2010, Vol. 362 Issue 12, p1150 

    A response by Susanne Toussaint and Herwig Gerlach to a letter to the editor about their article "Activated Protein C for Sepsis" in the December 31, 2009 issue is presented.

  • Drotrecogin Alfa (Activated): A Viewpoint by Derek C. Angus. Angus, D.C. // Drugs;2002, Vol. 62 Issue 4, p631 

    Examines the efficacy of drotrecogin alfa in reducing the mortality of patients with severe sepsis. Role of endogenous activated protein C in sepsis; Benefits and adverse effect of drotrecogin alfa therapy; Limited data on patient-centered outcomes associated with therapy.

  • Managing high-cost biotechnology products. Wong, Dorothy H.; Yang, Peggy // American Journal of Health-System Pharmacy;6/15/2003, Vol. 60 Issue 12, p1213 

    Offers ways to ensure the appropriate use of Drotrecogin alfa, a recombinant human activated protein C with U.S. Food and Drug Administration-approved labeling for use in the treatment of severe sepsis in adult. Medication-related issues; Criteria for use; Medication-use evaluation to track...

  • Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. Pastores, S.M. // Postgraduate Medical Journal;Jan2003, Vol. 79 Issue 927, p5 

    Recent studies have highlighted the close link between activation of the coagulation system and the inflammatory response in the pathophysiology of severe sepsis. The protein C anticoagulant pathway plays an integral part in modulating the coagulation and inflammatory responses to infection. In...

  • P & T PORTFOLIO.  // Drug Topics;2/18/2002, Vol. 146 Issue 4, p16 

    Evaluates the recombinant form of human protein C, Drotrecogin alfa for reducing mortality in adult patients with severe sepsis. Efficacy of the drug; Pharmacology; Warnings related to use.

  • Drotrecogin Alfa (Activated): A Viewpoint by Marcel Levi. Levi, M. // Drugs;2002, Vol. 62 Issue 4, p631 

    Examines the therapeutic use of protein C in the treatment of sepsis. Role of microvascular thrombosis in organ failure and mortality in patients with sepsis; Beneficial effect of activated protein C; Strategies to reduce mortality from sepsis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics